Table 2 Summary of results: quality and agreement
Variable | Total eligible | SANAD II total | Routine total | Difference* | Agreement** | Acceptable agreement*** |
Data variables relevant to the identification of eligible individuals and baseline assessment in SANAD II | ||||||
First-ever seizure (all Types) | 62 | 62 (100%) | 23 (37.1%) | P=0.002 | BA: − 84.09 (− 313.12–144.94) | 30 days |
First-ever seizure (tonic-clonic) | 62 | 43 (69.4%) | 22 (35.5%) | P=0.043 | BA: − 28.07 (− 123.72–67.58) | 30 days |
Diagnosis of epilepsy (baseline) | 78 | 78 (100%) | 37 (47.4%) | P=0.004 | BA: 30.54 (− 106.17–167.25) | 30 days |
Diagnosis of epilepsy (all-time) | 81 | 81 (100%) | 47 (58.0%) | P=0.195 | BA: − 26.23 (− 294.10–241.64) | 30 days |
Classification of seizures (baseline) | 37 | 37 (100%) | 37 (100%) | N/A | CK: 0.151 (P=0.018) | N/A |
Classification of seizures (all-time) | 47 | 47 (100%) | 47 (100%) | N/A | CK: 0.123 (P=0.019) | N/A |
Clinical investigations Magnetic resonance imaging | 98 | 72 (73.5%) | 9 (9.2%) | N/A | CK: 0.016 (P=0.602) | N/A |
Clinical investigations Computed tomography | 98 | 33 (33.7%) | 27 (27.6%) | N/A | CK: 0.406 (P< 0.001) | N/A |
Clinical investigations Electroencephalography | 23 | 18 (78.2%) | 8 (34.8%) | N/A | CK: 0.188 (P=0.131) | N/A |
Data variables relevant to the follow-up in SANAD II | ||||||
Date of first follow-up seizure | 98 | 61 (62.2%) | 22 (22.4%) | P=0.024 | BA: − 86.26 (− 386.41–213.89) | 30 Days |
Date of first follow-up tonic-clonic seizure | 98 | 35 (35.7%) | 20 (20.4%) | P=0.374 | BA: − 9.20 (− 436.46–418.06) | 30 Days |
Date 12-month remission achieved | 98 | 46 (46.9%) | 74 (75.5%) | P=0.004 | BA: 34.24 (− 115.48–183.96) | 30 Days |
Date of AED first prescription | 26 | 26 | 25 | P< 0.001 | BA: − 19.76 (− 67.86–28.34) | 90 Days |
Adverse events | 97 | 97 | 2 | - | - | - |
Planned healthcare attendances Baseline assessment | 98 | 98 (100%) | 87 (88.8%) | P< 0.001 | BA: 1.67 (− 7.21–10.55) | N/A |
Planned healthcare attendances Follow-up assessments | 350 | 350 (100%) | 317 (90.6%) | P< 0.14 | BA: 0.07 (− 4.33–4.47) | N/A |
Unplanned attendances: emergency | 94 | 52 (55.3%) | 37 (39.4%) | P=0.051 | BA: 0.05 (− 0.734–0.834) | N/A |
Unplanned attendances: inpatient | 94 | 12 (12.8%) | 19 (20.2%) | P=0.098 | BA: − 0.02 (− 0.72–0.68) | N/A |
Outcomes relevant to the follow-up in SANAD II | ||||||
Variable | Total eligible | SANAD II total | Routine total | SANAD II mean (95% CI) | Routine mean (95% CI) | Difference**** |
Days to first follow-up seizure | 98 | 61 (62.2%) | 22 (22.4%) | 325 (258–393) | 751 (680–822) | P< 0.001 |
Days to 12-month remission | 98 | 46 (46.9%) | 74 (75.5%) | 567 (515–618) | 393 (375–410) | P< 0.001 |